Abbott Gears Up For New Cholesterol Therapies, Winds Down Diagnostics

Building on two strategic initiatives announced last year - the acquisition of Kos and a collaboration with AstraZeneca - Abbott is gearing up to expand its commercial presence and late-stage pipeline in the cholesterol treatment market this year, President and Chief Operating Officer Richard Gonzalez said during the company's year-end sales and earnings call Jan. 24